|
|
Post by peppy on Jun 20, 2022 20:08:22 GMT -5
Number 4. AIDS is going to be difficult. AIDS is a reverse transcriptase. Reverse transcriptase (RT), also known as RNA-dependent DNA polymerase, is a DNA polymerase enzyme that transcribes single-stranded RNA into DNA. This enzyme is able to synthesize a double helix DNA once the RNA has been reverse transcribed in a first step into a single-strand DNA. But hey, through it out in the atmosphere, who knows. otherwise good to see. Many of big Pharma have a molecule that will be delivered better by IV in my option. Big Pharama is eyeing MNKD.  |
|
|
|
Post by jkendra on Jun 20, 2022 20:16:17 GMT -5
49:15 mark - Question on method of delivery... Will need a practical solution that does not need cold chain storage.
|
|
|
|
Post by letitride on Jun 20, 2022 21:02:49 GMT -5
Number 4. AIDS is going to be difficult. AIDS is a reverse transcriptase. Reverse transcriptase (RT), also known as RNA-dependent DNA polymerase, is a DNA polymerase enzyme that transcribes single-stranded RNA into DNA. This enzyme is able to synthesize a double helix DNA once the RNA has been reverse transcribed in a first step into a single-strand DNA. But hey, through it out in the atmosphere, who knows. otherwise good to see. Many of big Pharma have a molecule that will be delivered better by IV in my option. Big Pharama is eyeing MNKD. Peppy I dont understand the science but it has been done and is on going in Louisiana look at Mymetics it was part of a Horizon 2020 project in Europe |
|
|
|
Post by peppy on Jun 20, 2022 21:26:14 GMT -5
MYMETICS IS FOCUSED ON SEVERAL PATHWAYS TO DEVELOP PROPHYLACTIC VACCINES AND IMMUNOTHERAPIES WITH VIROSOMES: The ability to build a first line of defence against viruses entering the blood stream by focusing on the mucosal layer and generating mucosal and serum antibodies Improve the working of the immune system through generation of specific CD4+ and CD8+ T cells, especially needed for oncology immunotherapies The development of a thermostable and cold chain virosome vaccine formulations that can be administered through intra-nasal, sub lingual or oral routes. Using these pathways, our pipeline comprises vaccine candidates at various stages of clinical development under our own development or in collaboration with partners. MYMETICS’ HIV/AIDS PREVENTIVE VACCINE APPROACH Most HIV infections are sexually transmitted1 through direct contact of an infected mucosal membrane. Therefore, mucosal tissues represent the primary HIV entry door, as for many other pathogens. Mymetics’ vaccine targets earlier transmission and infection events that take place at the mucosal level during the first minutes or hours following exposure to HIV. Observations made on certain persons that are naturally resistant to HIV-12 infection revealed that despite their exposure to multiple HIV-1 positive individuals, they remain HIV-1 negative. This natural resistance is linked to the presence of mucosal antibodies against the HIV-1 present in their vaginal secretions. Similar resistance was also noted in males3. By using an influenza virosome and specifically designed antigens Mymetics’ aim is to transpose the mucosal antibody response in the vaccine design, therefore reproducing Mother Nature. Our preventive HIV-1 vaccine formulation triggers not only blood antibodies but also mucosal antibodies, whereas all the other vaccine candidates are aimed only at the production of blood antibodies. As a result, Mymetics' virosome based vaccine stimulates a defence mechanism effectively blocking entry of the virus at the mucosal level, the gateway of human infections. 100% PROTECTION IN VACCINATED PRIMATES In 2008, Mymetics performed a 12 months pre-clinical trial at ILAS (Institute of Animal Laboratory Science) in Beijing, China. The study involved several groups of female Chinese macaques, which received multiple challenges with the live virus. The results were overwhelmingly convincing: The group that was vaccinated with Mymetics’ preventive HIV vaccine candidate showed 100% protection, while the non-vaccinated control group was fully infected. These ground breaking scientific results have been presented at key world leading HIV congresses and have triggered strong attention from the HIV scientific community. See more ==================================================================================== Mucosal level. www.mymetics.com/vaccine-pipeline/hiv-aids/ |
|
